Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

Recruiting

Phase 3

Elagolix & ContraceptivesStudy Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain

Sponsor:

AbbVie

Code:

NCT04333576

Conditions

Endometriosis

Eligibility Criteria

Sex: Female

Age: 18 - 49

Healthy Volunteers: Not accepted

Interventions

Elagolix

Placebo

Combined Oral Contraceptive

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by AbbVie on 2025-03-25.